IMMUNOPHAGE BIOTECH
Immunophage Biotech is a Chinese high-tech pharmaceutic company which was established in 2016. The R&D center of the company is located in the Pujiang High-Tech Park, Shanghai, China. They are developing first-in-class immune-regulating medicines against cancer, autoimmune diseases and neurodegenerative disorders.
IMMUNOPHAGE BIOTECH
Industry:
Biotechnology Pharmaceutical
Founded:
2016-01-01
Address:
Shanghai, Shanghai, China
Country:
China
Website Url:
http://www.immunophage.com.cn
Total Employee:
11+
Status:
Active
Total Funding:
14.2 M USD
Technology used in webpage:
SPF Google Font API ASP.NET IIS ThemePunch IIS 7 Alibaba
Similar Organizations
Accent Therapeutics
Accent Therapeutics is a biopharmaceutical company.
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
IntraBio
IntraBio is a biopharmaceutical company.
Jiuzhou Yunjian
Jiuzhou Yunjian is a Beijing-based aerospace technology company.
Molecular Partners
Molecular Partners is a clinical-stage biopharmaceutical company.
Zentera Therapeutics
Zentera Therapeutics is a biopharmaceutical company.
Current Employees Featured
Founder
Investors List
Med-Fine Capital
Med-Fine Capital investment in Series A - Immunophage Biotech
Renjin Ziben
Renjin Ziben investment in Series A - Immunophage Biotech
Yijing Capital
Yijing Capital investment in Series A - Immunophage Biotech
Tao Capital
Tao Capital investment in Series A - Immunophage Biotech
Zibo Jinfang Hengjian Equity Investment Fund Partnership
Zibo Jinfang Hengjian Equity Investment Fund Partnership investment in Seed Round - Immunophage Biotech
Nanjing Yangzi Technology Venture Equity Investment Fund
Nanjing Yangzi Technology Venture Equity Investment Fund investment in Seed Round - Immunophage Biotech
Jinfang Hongrui Investment Management
Jinfang Hongrui Investment Management investment in Seed Round - Immunophage Biotech
Nanjing Xinnong Yangzi Modern Agricultural Industry Development Fund
Nanjing Xinnong Yangzi Modern Agricultural Industry Development Fund investment in Seed Round - Immunophage Biotech
Qingdao Zhongtai Huiyin Investment Management Partnership
Qingdao Zhongtai Huiyin Investment Management Partnership investment in Seed Round - Immunophage Biotech
Nanjing Enran Ruiguang Health Industry Investment Partnership
Nanjing Enran Ruiguang Health Industry Investment Partnership investment in Seed Round - Immunophage Biotech
Official Site Inspections
http://www.immunophage.com.cn
- Host name: 47.88.22.59
- IP address: 47.88.22.59
- Location: San Mateo United States
- Latitude: 37.5517
- Longitude: -122.33
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94402
More informations about "Immunophage Biotech"
Nanjing Immunophage Biotech Co.,Ltd
Immunophage is a clinical-stage biotech company focusing on discovering, developing, and commercializing innovative drugs globally for patients worldwide. The company strengthens its R&D pipeline by continually exploring novel …See details»
About-Nanjing Immunophage Biotech Co.,Ltd
In 2016, he became the Deputy Dean of the School of Translational Medicine, and Director of the Biomedical Research Center at Nanchang University, when he founded Immunophage Biotech …See details»
Immunophage Biotech - Crunchbase Company Profile & Funding
Immunophage Biotech raised CN¥200,000,000 / Series B from Zhongbo Juli. Discover more funding rounds . View All . Details. Edit Details Section. Industries . Biotechnology . …See details»
Immunophage Company Profile 2024: Valuation, Funding
Immunophage General Information Description. Developer of new drugs designed to treat cancer, autoimmune disease and neurodegenerative diseases. The company's drugs aim to inhibit …See details»
Immunophage Biotech - VentureRadar
Immunophage Biotech Co., Ltd (IMP) is a drug research and development company committed to discovering innovative drugs for novel therapeutic targets. IMP is devoted to discovering first …See details»
Immunophage - Products, Competitors, Financials, Employees ...
Immunophage is a clinical-stage biotech company focused on discovering, developing, and commercializing innovative drugs for various diseases. Use the CB Insights Platform to …See details»
Nanjing Immunophage Biotech Co. Ltd. - synapse.zhihuiya.com
了解Nanjing Immunophage Biotech Co. Ltd. (南京艾美斐生物医药科技有限公司)公司的药物管线，治疗领域，技术平台，以及它的8项临床试验, 46篇新闻和2篇文献，疾病领域:免疫系统疾 …See details»
Immunophage Biotech - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors ... Seed Round - Immunophage …See details»
Join Us-Nanjing Immunophage Biotech Co.,Ltd
5.Excellent communication, organization, and project management skills, with the ability to work effectively in a cross-functional team environment. 6.Proficient in English, with excellent …See details»
Congratulations to Immunophage Biotech on the US FDA …
Aug 27, 2021 About Immunophage Founded in 2016, Nanjing Immunophage Biotech Co. Ltd. is an innovative drug research and development company based on the world’s leading targets. …See details»
Platform-Nanjing Immunophage Biotech Co.,Ltd
￭ A well-established efficient platform for GPCR-targeting antibody drug discovery ￭ Obtained GPCR antibodies with high affinity, selectivity, and signal-blocking function, cross-reactive with …See details»
Immunophage's Second-Tier Global Innovative Drug for IBD …
Compared to marketed drugs such as adalimumab, vedolizumab, ustekinumab, and tofacitinib, IPG11406 has significant advantages in terms of safety, efficacy, and durability, making it a …See details»
Immunophage Biotech CEO and Key Executive Team | Craft.co
Immunophage Biotech's Founder, CEO is Guohuang Fan. Other executives include Jianfei Wang, CSO; Kin Chiu Fong, Board Director, Medicinal Chemist, Vice President. ... Source: …See details»
Immunophage Biotech - Craft
Immunophage Biotech is a pharmaceutic company. Its cancer therapies aim to inhibit tumor growth and Myeloid-derived suppressor cell production, while the company's other therapies …See details»
Immunophage Biotech - VentureRadar
Similar Companies: Dansk Biotek Unknown n/a DANISH BIOTECH is a trade organization for Danish biotech companies with the aim to promote opportunities for biotechnology research, …See details»
Immunophage Achieves 6 INDs for Solid Tumors and Autoimmune …
In addition to IPG1094, another promising candidate in Immunophage's rapidly advancing first-tier clinical pipeline is IPG7236. IPG7236 is a CCR8 antagonist, its potential in treating various …See details»
Pipeline-Nanjing Immunophage Biotech Co.,Ltd
Cpyright © 2023 Nanjing Immunophage Biotech Co.,Ltd. All Rights Reserved. 苏ICP备2022026466号-1 苏公网安备 32011202000830号 苏公网安备 32011202000830号See details»
IPG0521 - Drug Targets, Indications, Patents - Synapse
IPG0521: a CCR8 inhibitor Drug, Initially developed by Nanjing Immunophage Biotech Co. Ltd., Now, its global highest R&D status is IND Application, Mechanism: CCR8 inhibitor(C-C …See details»
Immunophage Biotech Co., Ltd has successfully completed the …
Immunophage Achieves 6 INDs for Solid Tumors and Autoimmune Diseases in Six Months; Mar 13, 2023 Immunophage Biotech Co., Ltd has successfully completed the first phase of Series …See details»
IPG6620 - Drug Targets, Indications, Patents - Synapse
IPG6620, Initially developed by Nanjing Immunophage Biotech Co. Ltd., Now, its global highest R&D status is Preclinical, Therapeutic Areas: Nervous System Diseases, Active Indication: …See details»